GlassScriptPhysician profile
Matthew Aaron Meadows
NPI 1275599219
$19,957.25
in general payments reported to CMS, 2019-2025
50 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $820 · 2021: $1,008 · 2022: $6,069 · 2023: $8,999 · 2024: $1,264 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,597 · Food and Beverage: $3,521 · Travel and Lodging: $2,889 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,596.91 |
| Food and Beverage | $3,520.69 |
| Travel and Lodging | $2,888.98 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $12,253.42 | 2022-2025 | Titan, Speedicath |
| Procept Biorobotics Corporation | $957.89 | 2020-2025 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $785.33 | 2019-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), General - Erectile Dysfunction, Rezum Generator |
| Janssen Biotech, INC. | $752.86 | 2019-2025 | Erleada, Akeega, Balversa |
| Antares Pharma, INC. | $595.64 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $443.13 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $438.53 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $397.28 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $336.20 | 2019-2025 | |
| Axonics, INC. | $309.62 | 2022-2024 | Axonics, Bulkamid |
| Olympus America INC. | $297.11 | 2020-2023 | Itind System |
| Pfizer INC. | $186.45 | 2019-2025 | |
| Tolmar, INC. | $178.85 | 2023-2025 | Eligard, Jatenzo |
| Myovant Sciences INC. | $152.87 | 2021-2022 | |
| Endo USA, INC. | $129.82 | 2024-2025 | Xiaflex |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.